

Table S1. Online survey questionnaire.

Q1	Have you already worked with patients treated with cannabinoid drugs?
	☐ Yes
	☐ No
Q2	Were any of these in a paediatric age (0-18 years)?
	☐ Yes
	☐ No
Q3	Were any of these children/adolescents diagnosed with cerebral palsy?
	☐ Yes
	☐ No
Q4	Did you ever experience a situation in which the prescription of medical cannabinoids in this type of patients was debated, but for some reason not prescribed?
	☐ Yes
	☐ No
Q5	Before we continue with the survey, please inform us how you answered the first 4 questions. (If at least one of the questions Q1-Q4 was answered affirmatively, access to Q6-Q34 was provided.)
	☐ I answered the first four questions all with no
	☐ I answered at least one of the first four questions with a yes
Q6	What is your country of birth?
Q7	In what year were you born? (Enter 4-digit birth year; for example, 1976)
Q8	What is your gender?
	☐ Male
	☐ Female
Q9	Where did you attain your medical degree (enter city and country)?
Q10	What is your medical specialization?
	☐ Paediatrics
	☐ Neurology
	☐ Neurosurgery
	☐ Child and adolescent psychiatry and psychotherapy
	☐ Anaesthesia
	☐ Medical genetics
	☐ Psychiatry and psychotherapy
	☐ Radiology
	☐ Physical medicine and rehabilitation

☐ *General internal medicine*

☐ *Orthopaedics*

☐ *Paediatric surgery*

☐ *Other (Specify)*

Q11 How many years of experience do you have in your specialty? (If more than one specialty, please specify the numbers for every single one, in the comment box below.)

☐ *0-5*

☐ *6-10*

☐ *11-15*

☐ *>15*

Q12 Have you also attained a paediatric subspecialty?

☐ *Yes*

☐ *No*

Q13 Please specify your subspecialty.

☐ *Developmental paediatrics*

☐ *Paediatric rehabilitation medicine*

☐ *Paediatric palliative care*

☐ *Neuropediatrics*

☐ *Paediatric oncology-haematology*

☐ *Other (specify)*

Q14 How many years of experience do you have in your subspecialty? (If more than one subspecialty, please specify the numbers for every single one, in the comment box below.)

☐ *0-5*

☐ *6-10*

☐ *11-15*

☐ *>15*

Q15 In which country do you currently work?

Q16 What kind of institution do you currently work in?

☐ *Hospital*

☐ *Private practice*

☐ *Joined practice*

☐ *University hospital*

☐ *Other (specify)*

Q17 How were you introduced to medical cannabinoids?

☐ *As part of my education*

☐ *Participation in a congress on the theme*

☐ *Individual learning on the subject*

☐ *Through the advice of other collaborators*

-
- ☐ *Through education provided by my institution*
- ☐ *Through education provided by pharmaceutical companies*
- ☐ *Other (specify)*
-

Q18 How many years have you been treating children diagnosed with cerebral palsy?

- ☐ *0-5*
- ☐ *6-10*
- ☐ *11-15*
- ☐ *16-20*
- ☐ *>20*
-

Q19 How many of your patients diagnosed with cerebral palsy are/were treated with medical cannabinoids?

Q20 How long have you been working with cannabinoids for therapeutic purposes? (years)

- ☐ *0-5*
- ☐ *6-10*
- ☐ *11-15*
- ☐ *16-20*
- ☐ *>20*
-

Q21 What is, in your experience, the most important indication to start a treatment with cannabinoids in children with cerebral palsy?

- ☐ *Pain*
- ☐ *Epilepsy*
- ☐ *Sleep disturbance*
- ☐ *Spasticity*
- ☐ *Behavioural problems*
- ☐ *None*
- ☐ *Other (specify)*
-

Q22 How would you assess, on a scale from 1 to 5, the effectiveness of the therapy in the context of the indication above? (Scale values are specified below.)

- ☐ *Insignificant*
- ☐ *Weak*
- ☐ *Moderate*
- ☐ *Strong*
- ☐ *Excellent*
-

Q23 Would you also consider further indications?

- ☐ *Pain*
- ☐ *Spasticity*
- ☐ *Epilepsy*
- ☐ *Behavioural problems*
- ☐ *Sleep disturbance*

☐ No

☐ Other (specify)

Q24 In which context was the therapy mainly started?

☐ First line treatment

☐ Second line treatment

☐ Co-medication

☐ Palliative treatment

☐ Other (specify)

Q25 Have there been any criteria that prevented/suggested not to undertake this therapy in paediatric patients?

☐ Age of the patient

☐ Parents' wishes

☐ Other pathologies (contraindications)

☐ Lack of cost coverage by the health insurance

☐ Legal or administrative hurdles

☐ Other medicines (drug interactions)

☐ None

☐ Other (specify)

Q26 Which type of drug has mostly been used? (The list below only lists the preparations offered in Switzerland, if you have prescribed other preparations, please specify below.)

☐ Cannabis sativa spray (Sativex): viscous extract of Δ^9 -THC - and CBD, standardized contents: 2.7/2.5 mg per spray

☐ Dronabinol solution: synthetically produced Δ^9 -THC, standardized dronabinol content 2,5%

☐ Cannabis tincture: alcoholic drop solution, standardized Δ^9 -THC and CBD contents: 11/22mg per g

☐ Cannabis oil: oily drop solution, standardized Δ^9 -THC and CBD contents: 11/24mg per g

☐ Sativa oil: oily drop solution, standardized Δ^9 -THC and CBD contents (Sativex equivalent ratio ☐ 2,7/2,5 mg per g)

☐ Self-medication: different contents of Δ^9 -THC, CBD, and other cannabinoids

☐ Other (specify)

Q27 What was the maximum dosage prescribed for the respective preparations? (Please enter how it was prescribed and the dose of THC and/or CDB in mg/kg/day.)

Q28 Was there a habituation effect noticed?

☐ Yes

☐ No

Q29 Was a dose adjustment necessary as a result?

☐ Yes

☐ No

Q30 Were any important short-term adverse events noticed?

- ☐ *Anxiety*
- ☐ *Asthenia*
- ☐ *Balance*
- ☐ *Confusion*
- ☐ *Depression*
- ☐ *Diarrhoea*
- ☐ *Disorientation*
- ☐ *Dizziness*
- ☐ *Dry mouth*
- ☐ *Dyspnoea*
- ☐ *Euphoria*
- ☐ *Eye disorders*
- ☐ *Fatigue*
- ☐ *Hallucination*
- ☐ *Nausea*
- ☐ *Paranoia*
- ☐ *Psychosis*
- ☐ *Seizures*
- ☐ *Somnolence*
- ☐ *Vomiting*
- ☐ *Weakness*
- ☐ *None*
- ☐ *Other (specify)*

Q31 What consequences have they had for the continuation of the therapy?

- ☐ *Irrelevant*
- ☐ *Drug dose adjustment*
- ☐ *Therapy stop*
- ☐ *Other (specify)*

Q32 Were any important long-term adverse events noticed?

- ☐ *Cardiovascular disease*
- ☐ *Respiratory disease*
- ☐ *Cancer*
- ☐ *Psychotic disorders*
- ☐ *Suicide or suicidal thoughts*
- ☐ *None*
- ☐ *Other (specify)*

Q33 On a scale from 1 to 5, please give us below a personal rating for your experience with the use of these therapies in children with cerebral palsy.

- ☐ *Bad*
- ☐ *Acceptable*

- ☐ Average
- ☐ Good
- ☐ Outstanding

Q34 Remarks.

Table S2. Characteristics of the participating physicians by region.

	Total n=70, (%)	Switzer- land n=23, (%)	Europe exclud- ing Swit- zerland n=27, (%)	North America n=18, (%)	Aus- tralia n=2, (%)	p- value ^{3,4}
Sex						0.07
Male	25 (36)	0 (0)	5 (19)	0 (0)	0 (0)	
Female	43 (61)	11 (48)	20 (74)	10 (56)	2 (100)	
Unknown	2 (3)	12 (52)	2 (7)	8 (44)	0 (0)	
Age in years (interquartile range)	48 (42-57)	49 (46-57)	51 (42-61)	41.5 (38-55)	40 (38-42)	
Workplace¹						<0.001
Any hospital	56 (80)	20 (87)	16 (59)	17 (94)	2 (100)	
University hospital	23 (33)	11 (48)	5 (19)	7 (39)	0 (0)	
General hospital	27 (39)	9 (39)	10 (37)	6 (33)	2 (100)	
University and general hospital	6 (9)	1 (4)	1 (4)	4 (22)	0 (0)	
Rehabilitation centre	12 (17)	0 (0)	11 (41)	1 (6)	0 (0)	
Private/Joined practice	2 (3)	2 (9)	0 (0)	0 (0)	0 (0)	
Work experience with cannabinoids in years						0.80
0-5	64 (91)	21 (91)	25 (93)	16 (89)	0 (0)	
6-10	5 (7)	2 (9)	2 (7)	1 (6)	2 (100)	
11-15	1 (1)	0 (0)	0 (0)	1 (6)	0 (0)	
Indication (overall)^{1,2}						
Epilepsy	48 (69)	17 (74)	13 (48)	16 (89)	2 (100)	0.01
Spasticity	45 (64)	19 (83)	15 (56)	10 (56)	1 (50)	0.08
Pain	44 (63)	19 (83)	14 (52)	10 (56)	1 (50)	0.06
Behavioural problems	12 (17)	5 (22)	5 (19)	1 (6)	1 (50)	0.41
Sleep disturbance	11 (16)	5 (22)	3 (11)	2 (11)	1 (50)	0.57
Dystonia	8 (11)	2 (9)	4 (15)	2 (11)	0 (0)	0.90
None	5 (7)	1 (4)	4 (15)	0 (0)	0 (0)	0.21
Context of prescription						0.06

Co-medication	28 (40)	10 (44)	7 (26)	10 (56)	1 (50)	
Second line treatment	16 (23)	6 (26)	4 (15)	4 (22)	0 (0)	
Palliative treatment	7 (10)	5 (22)	2 (8)	0 (0)	0 (0)	
First line treatment	2 (3)	0 (0)	1 (4)	1 (6)	0 (0)	
Parents initiated treatment	2 (3)	0 (0)	2 (7)	0 (0)	0 (0)	
Not applicable	6 (9)	1 (4)	4 (15)	1 (6)	0 (0)	
No response	9 (13)	1 (4)	7 (26)	1 (6)	0 (0)	
Reasons for not initiating cannabinoids¹						
Lack of cost coverage	24 (34)	5 (22)	10 (37)	9 (50)	0 (0)	0.18
Age of the patient	19 (27)	8 (35)	4 (15)	7 (39)	0 (0)	0.12
Lack of evidence on effectiveness and side effects	15 (21)	4 (17)	8 (30)	3 (17)	0 (0)	0.57
Parents wish	13 (19)	4 (17)	4 (15)	5 (28)	0 (0)	0.59
Drug interaction	10 (14)	1 (4)	4 (15)	5 (28)	0 (0)	0.13
Other co-morbidities	3 (4)	0 (0)	1 (4)	2 (11)	0 (0)	0.26
None	8 (11)	6 (26)	1 (4)	1 (6)	0 (0)	0.43

¹Multiple responses possible

²Most important and further indications grouped

³Excluding Australia due to low sample size.

⁴Chi-square, Fisher's exact, or Wilcoxon rank-sum tests